We are now witnessing a massive cultural retreat from the most controversial elements of activist-driven gender ideology aimed at children. And corporate America is a major part of that shift.
For years, the gender ideology narrative captured our society’s most prominent institutions. The notion that the provision of hormone regimens, puberty blockers, and gender transition surgeries was the only compassionate response to young people facing confusion about their gender morphed from a fringe theory into a near-unquestionable dictate during the last decade. In 2019, a doctor who believed in the Biblical and scientific notion of differences between the sexes was told that his views were “incompatible with human dignity.” Parents of children struggling with gender dysphoria were often presented with a ghoulish, faux-paternalistic ultimatum by therapists and psychologists: “Would you rather have a dead daughter or a live son?”
Perhaps the most impactful driver of this narrative was the boardroom. The dictates of gender ideology were not only pushed forward by activists but also supported by some of the most recognizable brands on Earth. One of the most high-profile examples was Amazon: scholar Ryan T. Anderson, whose 2018 book When Harry Became Sally offered a thoughtful Christian response to gender ideology, had to fight through a book ban and smears of “hate speech,” before it could be sold in the world’s largest online market. Countless companies, from Apple to Target, were participating with corporate activist organizations like the Human Rights Campaign, one of the major promoters of gender ideology in corporate America.
In the 2010s and early 2020s, it was perfectly reasonable to believe that the way major companies handled gender ideology was less about science and more about placating goalpost-shifting activists. And then, as so often happens with activist movements, the goalposts got shifted too far. It wasn’t just adult choice that was the focus of gender ideology. It was about the attempted normalization of surgical interventions for children. That was when the momentum shifted.
Three recent occurrences illustrate just how quickly the tide is turning.
First, a 22-year-old ‘detransitioner’ — someone who regrets their gender transition — just won a $2 million lawsuit against the New York doctors who approved her surgery. Fox Varian, who had a double mastectomy (surgical removal of both breasts) when she was just 16 years old, is the first detransitioner to take a medical malpractice case to trial and win.
That ruling came on January 30. On February 3, the American Society of Plastic Surgeons released a statement asserting that “there is insufficient evidence demonstrating a favorable risk-benefit ratio for … gender-related endocrine and surgical interventions in children and adolescents.”
Days later, the American Medical Association announced its agreement: “The AMA agrees… surgical interventions in minors should be generally deferred to adulthood.”
Let’s be clear about what that means: in the span of approximately a week, two absolutely critical points have been proven about gender ideology: (1) performing gender transition surgeries on children is a source of major legal liability, and (2) the medical consensus does not neatly support the necessity of such treatments.
These are precisely the arguments we have made to companies for years about their healthcare coverage. For companies that spent the early 2020s placating activists pushing gender ideology, the mid 2020s may be a painful reckoning with how out-of-touch with reality those activists truly were.
Activist groups like the Human Rights Campaign told companies that covering hormone regimens and transition care were prudent ways to minimize risk. It’s incredibly apparent that this was a wild guess at best, and a cleverly worded activist ploy at worst. As the era of corporate wokeness comes to an end, companies seeking to stay politically neutral and avoid becoming entrenched in culture war issues (remember, companies have a fiduciary duty to do this) are taking a serious look at their healthcare coverage.
For companies that cover gender transition care for adults, do they also cover detransition care? If not, that hardly reads as politically neutral. Do companies have clear stances on not covering gender transition care for children? These are the questions that we, as corporate engagement professionals, are asking hundreds of companies.
Some companies are setting the standard. Walmart, the world’s largest company, publishes its full Associate Benefits Guide, which includes a clear carve-out prohibiting health plan administrators from providing transgender medical interventions to minors. The company has also been incredibly constructive in engaging with its shareholders on this issue. Other companies should follow Walmart’s example. You’d be amazed by how many haven’t. But the winds are blowing in our favor.
One major example of the large-scale retreat is the widespread drop in support for the Human Rights Campaign, whose ‘Corporate Equality Index’ grades companies in part by their adherence to activist criteria surrounding hormone regimens, transition surgery, and the like. In 2025, almost 380 Fortune 500 companies participated in the Index. In 2026? Fewer than 150. Many of the major names that ceased participation, including Capital One, Goldman Sachs, and Google (Alphabet), are companies we’ve engaged with surrounding these issues.
If these signs are any indication, there’s much more to come. As the consequences of such treatments become more widely understood, by major companies, providers, and especially insurers, we may well see the forming of a new consensus, the one that always should have been: the dictates of gender ideology, that promoted and supported major and often irreversible medical interventions for children, are being rejected by the brands that make up our capital markets. For the sake of America’s children, that rejection can’t come fast enough.
* * *
Isaac Willour is an award-winning journalist focusing on race, culture, and American conservatism, as well as a corporate relations analyst at Bowyer Research. His work has been featured at outlets including USA Today, The Wall Street Journal, The New York Times Opinion, C-SPAN, and The Daily Wire. He is a member of the Young Voices contributor program and can be found on X @IsaacWillour.
The views expressed in this piece are those of the author and do not necessarily represent those of The Daily Wire.
.png)
.png)
